AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00743886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: injection onto injured area in ligament dose: 3-6mg
Study NCT00743886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: injection of 6 cc of saline into injured area
Study NCT00418288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucagon-like-peptide-1
Description: intravenous infusion of 1.2pmol/kg/min for 7 hours
Study NCT00418288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous infusion of 1.2pmol/kg/min
Study NCT02783560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Sleep Train Program
Description: This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
Study NCT02783560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Sleep Train Program
Description: This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
Study NCT02783560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Family Mealtimes Program
Description: This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
Study NCT00119639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006, Nexavar)
Description: All subjects were given a open-label, single dose of 400mg sorafenib
Study NCT01644214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 month follow up for pessary check in the clinic setting
Description: The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
Study NCT02478333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (250 mg)
Description: Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
Study NCT02478333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (500 mg)
Description: Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
Study NCT02478333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg)
Description: Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
Study NCT02478333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
Study NCT01878266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Arm (1)
Description: A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
Study NCT02783560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Family Mealtimes Program
Description: This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
Study NCT03822884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa 40000 UNT/ML
Description: 40.000 UI subcutaneous single dose
Study NCT03822884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa 40000 UNT/ML
Description: 40.000 UI subcutaneous single dose
Study NCT01878266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Arm (2)
Description: The total dose to 4500 cGy in 15 fractions in 3 weeks
Study NCT01878266 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional Arm (3)
Description: A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
Study NCT03670485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study NCT01214850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)
Study NCT01214850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine
Study NCT01214850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis vaccine
Study NCT01705301 — intervention group
Intervention type: DEVICE
Intervention: WINCS
Description: The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
Study NCT04012892 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: CD19 CART
Study NCT04470115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
Study NCT04470115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks
Description: The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
Study NCT01844674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
Study NCT01844674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
Study NCT05621694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Easy
Description: A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
Study NCT02053857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Study NCT02053857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-P
Study NCT02053857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study NCT02053857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT01952522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weighted brace
Description: People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
Study NCT02415985 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/r will be supplied by NHSO/GPO
Description: 200/50 mg tablet LPV/rtv
Study NCT02415985 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifabutin
Study NCT01200914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Description: The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
Study NCT01200914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA alone without use of the GORE VIABAHN
Description: Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
Study NCT01616927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide will be administered once every 4 weeks as a subcutaneous injection
Study NCT02165527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lunar iXDA scan
Description: Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
Study NCT01865773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFR dialysis
Description: HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
Study NCT02803463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open appendectomy with peritoneal closure
Description: open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
Study NCT02803463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open appendectomy without peritoneal closure
Description: open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
Study NCT04174261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Preprocedural ticagrelor loading and standard dose thereafter
Study NCT04174261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Preprocedural ticagrelor loading and standard dose thereafter
Study NCT04174261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Preprocedural remote ischemic preconditioning on the non-dominant arm
Study NCT04174261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Preprocedural remote ischemic preconditioning on the non-dominant arm
Study NCT04174261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Preprocedural clopidogrel loading and standard dose thereafter
Study NCT04174261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Preprocedural clopidogrel loading and standard dose thereafter
Study NCT02196831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesamorelin
Study NCT02196831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance that looks like tesamorelin
Study NCT02747160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Anxiety from Cancer (MAC)
Description: The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
Study NCT01855373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEAK ATP® with GlycoCarn®
Description: PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
Study NCT01855373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEAK ATP®
Description: PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
Study NCT01855373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlycoCarn®
Description: GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
Study NCT01855373 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo: 2 capsules twice daily on an empty stomach
Study NCT00134420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutropin AQ
Description: Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arginine and Clonidine Stimulation Testing
Description: This testing was done to determine growth hormone status prior to starting treatment.
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arginine and Clonidine Stimulation Testing
Description: This testing was done to determine growth hormone status prior to starting treatment.
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Growth Factors Laboratory Testing
Description: This involved assessment of growth factors such as IGF#1 before treatment was initiated.
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Growth Factors Laboratory Testing
Description: This involved assessment of growth factors such as IGF#1 before treatment was initiated.
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neuropsychological Testing
Description: This testing was done prior to treatment and at the end of treatment.
Study NCT00134420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Testing
Description: This testing was done prior to treatment and at the end of treatment.
Study NCT04134403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STASIS
Description: Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
Study NCT00573287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: clozapine--tabs, 450mg. max, daily, 24 weeks
Study NCT00573287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone--tabs, 6mg max, daily, 24 weeks
Study NCT01890720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNPWT
Description: The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
Study NCT01890720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative wound dressing
Description: A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
Study NCT03320694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
Study NCT03320694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
Study NCT00736047 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NIC002
Study NCT00736047 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01773447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Set-back suture
Study NCT01773447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical mattress suture
Study NCT04089800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone based multimedia application
Description: The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
Study NCT01044329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal, 1.25 mg, 3 times, one month apart.
Study NCT01044329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal, 2 mg, 2 times, two months apart.
Study NCT02492737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Study NCT02444000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy alone
Description: PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
Study NCT02444000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy+PCV chemotherapy
Description: Radiotherapy followed by 6 cycles of PCV
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinfukang Koufuye
Description: 30ml per time, tid, po (d6-21, q21)
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2,ivgtt 30mins, d1
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2,ivgtt 30mins, d1
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m2, ivgtt 30mins, d1
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2, ivgtt 30mins, d1
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2, ivgtt >2h, d1
Study NCT03269162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2, ivgtt >2h, d1
Study NCT00882570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Study NCT00882570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
Study NCT05349253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic extracts
Description: One intake in total
Study NCT05349253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intake in total
Study NCT00728143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Highly viscous polysaccharide enriched biscuits
Description: 10 g of highly viscous polysaccharide
Study NCT00728143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highly viscous polysaccharide enriched biscuits
Description: 10 g of highly viscous polysaccharide
Study NCT01341392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study NCT01932606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrite
Description: Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
Study NCT01932606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo for Nitrite
Description: Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
Study NCT02783625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study NCT02783625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02783625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvelisib
Study NCT04480879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 nebuliser
Description: Nebuliser suspension
Study NCT04480879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 Monodose DPI presented in capsules
Description: AZD8154 Monodose DPI formulation delivered dose
Study NCT04480879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD8154 Placebo Monodose DPI presented in capsules
Description: The dose correspond to AZD8154 Monodose DPI formulation